{
    "id": "dbpedia_8098_2",
    "rank": 58,
    "data": {
        "url": "https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2096/simcere-pharmaceutical-group-shares/news/simcere-pharmaceutical-group-full-year-2023-earnings-eps-bea",
        "read_more_link": "",
        "language": "en",
        "title": "Simcere Pharmaceutical Group Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag",
        "top_image": "https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299",
        "meta_img": "https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299",
        "images": [
            "https://simplywall.st/news/images/blue-bear.svg",
            "https://simplywall.st/cdn-cgi/image/width=1200,height=411,fit=cover,format=auto/https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299",
            "https://images.simplywall.st/asset/chart/33364824-earnings-and-revenue-growth-1-dark/1714169584276",
            "https://images.ctfassets.net/n07nr2koi959/220TWz80MMu5IKd31MX2Mh/5baf073475c70362f71c7471b9e72a3c/portrait.jpg?fit=thumb&w=64&h=64",
            "https://images.ctfassets.net/n07nr2koi959/220TWz80MMu5IKd31MX2Mh/5baf073475c70362f71c7471b9e72a3c/portrait.jpg?fit=thumb&w=64&h=64",
            "https://images.ctfassets.net/n07nr2koi959/220TWz80MMu5IKd31MX2Mh/5baf073475c70362f71c7471b9e72a3c/portrait.jpg?fit=thumb&w=64&h=64",
            "https://simplywall.st/news/images/blue-bear.svg",
            "https://simplywall.st/news/images/blue-bear.svg",
            "https://simplywall.st/news/images/blue-bear.svg",
            "https://simplywall.st/news/images/ios-badge.png",
            "https://simplywall.st/news/images/play-badge.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Simply Wall St"
        ],
        "publish_date": "2024-04-27T00:20:53.892000+00:00",
        "summary": "",
        "meta_description": "Simcere Pharmaceutical Group ( HKG:2096 ) Full Year 2023 Results Key Financial Results Revenue: CN¥6.61b (up 4.5% from...",
        "meta_lang": "",
        "meta_favicon": "/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2096/simcere-pharmaceutical-group-shares/news/simcere-pharmaceutical-group-full-year-2023-earnings-eps-bea",
        "text": "Simcere Pharmaceutical Group ( ) Full Year 2023 Results\n\nKey Financial Results\n\nRevenue: CN¥6.61b (up 4.5% from FY 2022).\n\nNet income: CN¥714.8m (down 23% from FY 2022).\n\nProfit margin: 11% (down from 15% in FY 2022). The decrease in margin was driven by higher expenses.\n\nEPS: CN¥0.27 (down from CN¥0.36 in FY 2022).\n\n2096 Products In Clinical Trials\n\nPhase I: 11.\n\nPhase II: 8.\n\nPhase III: 7.\n\n2096 Post-Clinical Trial Products\n\nPre-registration: 3.\n\nApproved (during full year): 3.\n\nLaunched (during full year): 1.\n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\n\nSimcere Pharmaceutical Group EPS Beats Expectations, Revenues Fall Short\n\nRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 1.9%.\n\nLooking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Hong Kong.\n\nThe company's shares are up 2.9% from a week ago.\n\nRisk Analysis\n\nIt's still necessary to consider the ever-present spectre of investment risk. , and understanding this should be part of your investment process."
    }
}